Blue Sail Medical Co Ltd

Blue Sail Medical maintains a capital structure characterized by significant leverage and constrained liquidity. The company holds total assets of 16.76 billion CNY against total liabilities of 9.60 billion CNY, resulting in total equity of 7.17 billion CNY. Long-term debt stands at 5.23 billion CNY, yielding a debt-to-equity ratio of 0.73. Liquidity is tight, with a current ratio of 0.85, indicating that current liabilities exceed current assets. The firm generates positive operating cash flow of 457.7 million CNY, but this is insufficient to cover capital expenditures of 553.0 million CNY, resulting in negative free cash flow of -946.4 million CNY. The market capitalization is 5.26 billion CNY, trading at a price-to-book ratio of 0.73, suggesting the market values the company below its book value.

Profitability metrics indicate significant operational challenges. The company reports revenue of 5.74 billion CNY but incurs a gross profit of only 808.3 million CNY, implying a gross margin of approximately 14.1%. Operating income is negative at -627.5 million CNY, and net income is -758.9 million CNY. Return on equity is -10.59%, and return on assets is -4.53%, reflecting the inability to generate returns on the invested capital base. The negative EV/EBITDA of -16.72 further underscores the lack of earnings before interest, taxes, depreciation, and amortization. Without cohort median data for direct comparison, these figures suggest a business model currently under pressure, likely due to high operating costs or pricing pressures in the medical device sector.

Segment and geographic revenue mix data is not available in the provided input. Consequently, specific insights into revenue concentration by product line or region cannot be derived. The analysis must rely on aggregate financial figures, which show a substantial revenue base of 5.74 billion CNY, indicating a large operational scale despite profitability issues.

Historical period data for revenue and net income trends is absent from the input. Therefore, the growth trajectory cannot be assessed through year-over-year or quarter-over-quarter comparisons. The current snapshot shows a large revenue figure relative to the market cap (EV/Revenue of 1.83), but without historical context, it is unclear whether this represents a peak, a trough, or a stable state.

Risk assessment highlights medium liquidity risk and low dilution risk. The key flag notes that net cash is negative after subtracting total debt, reinforcing the liquidity concerns identified by the current ratio of 0.85. The negative free cash flow of -946.4 million CNY adds to the liquidity pressure, as the company is consuming cash to fund operations and investments. The low dilution risk suggests that the company is not currently issuing significant new shares, which is supported by the identical basic and diluted share counts of 1.01 billion shares.

Recent filing, news, and transcript observations are not provided in the input. Therefore, no specific recent events can be cited to explain the current financial position. The analysis relies solely on the static financial snapshot and risk assessment provided.